Physician profile
Jamir E Mireles
NPI 1881804540
$4,385.37
in general payments reported to CMS, 2019-2025
21 companies · $902 in 2025
The $902 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $174 · 2020: $304 · 2021: $335 · 2022: $555 · 2023: $1,231 · 2024: $884 · 2025: $902.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,002 · Education: $15.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,001.52 |
| Education | $15.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,884.42 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $293.59 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $259.61 | 2020-2025 | Trelegy Ellipta |
| Amgen INC. | $150.44 | 2020-2024 | Otezla, Repatha, Krystexxa |
| Exact Sciences Corporation | $117.85 | 2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $106.97 | 2020-2022 | |
| Lilly USA, LLC | $101.21 | 2023-2025 | Jardiance, Zepbound, Mounjaro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $94.42 | 2023 | Lifevest |
| Pfizer INC. | $50.17 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $47.67 | 2021 | |
| Dexcom, INC. | $45.31 | 2025 | Dexcom G6 Transmitter |
| Hikma Pharmaceuticals USA | $44.36 | 2022 | |
| Astellas Pharma US INC | $36.34 | 2023-2024 | Veozah |
| Phathom Pharmaceuticals, INC. | $29.06 | 2024-2025 | Voquezna |
| Abbott Laboratories | $22.65 | 2024 | Freestyle Libre |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $20.37 | 2025 | Zoryve |
| Medtronic Vascular, INC. | $20.12 | 2019 | |
| Almatica Pharma LLC | $17.77 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.39 | 2024 | Trintellix |
| Boston Scientific Corporation | $15.04 | 2020 | |
| Sanofi-Aventis U.S. LLC | $12.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamir Mireles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.